Wegovy® (semaglutide) carries an official list price of approximately $1,350 per month for both the weekly injection pen and the daily oral pill, but out-of-pocket cash prices without insurance range from $199 to $399 monthly for injections and $149 to $299 for the pill.
As Noom reported, patients paying without traditional insurance or whose health plans exclude weight-management therapies face changing financial conditions governed by manufacturer direct-to-consumer pricing models, temporary government programs, and upcoming list price reductions set for January 1, 2027.
Novo Nordisk Slashes Wegovy List Price
- List Price Shift: Novo Nordisk (NYSE: NVO) is set to reduce the official monthly list price of Wegovy® from approximately $1,350 to $675 on January 1, 2027.
- Cash-Pay Alternatives: Uninsured patients can currently access the injection pen through NovoCare Pharmacy for $199 to $399 per month, while the oral pill spans $149 to $299 per month depending on dosage.
- Government Intervention: Eligible Medicare Part D beneficiaries can access Wegovy® through the temporary Medicare GLP-1 Bridge Program at a flat copay of $50 per month through December 31, 2027.
Insurance Coverage Varies Across Private Carriers
The list price for Wegovy is about $1,350 for a 28-day supply, which adds up to about $16,200 annually, representing a significant financial hurdle for patients lacking comprehensive health plan benefits. GoodRx notes that insurance coverage for chronic weight management medications varies widely across private carriers, with some major providers implementing strict prior authorization criteria or excluding GLP-1 receptor agonists entirely.
For patients with qualifying commercial insurance policies that cover the medication, manufacturer savings cards can reduce out-of-pocket expenses to as little as $25 per month, though savings are typically capped at $100 per month. Optum Perks highlights that government-funded insurance programs—including Medicare, Medicaid, and Tricare—are excluded from these commercial savings card offers, creating a distinct financial divide for beneficiaries enrolled in public healthcare systems.
Evaluating the Oral Pill Versus the Weekly Injection Pen
The introduction of the oral Wegovy® pill in early 2026 expanded treatment delivery options beyond the traditional subcutaneous injection pen first approved by the U.S. Food and Drug Administration in 2021. Patients evaluating out-of-pocket costs must weigh format-specific pricing tiers established through direct distribution programs.
According to pharmacy pricing disclosures, the oral pill generally trades at a discount compared to the injectable formulation. Cash-pay prices for the oral pill range from $149 to $299 per month through NovoCare Pharmacy and participating retail chains such as Costco, Walmart, CVS, Walgreens, and Amazon Pharmacy. By comparison, the weekly injection pen spans $199 to $399 per month for self-pay accounts.
| Payment Scenario | Injection Monthly Cost | Pill Monthly Cost | Eligibility Criteria |
|---|---|---|---|
| Full List Price | $1,350 ($675 on Jan 1, 2027) | $1,350 ($675 on Jan 1, 2027) | Uninsured / Full cash retail |
| NovoCare Self-Pay | $199 – $399 | $149 – $299 | Uninsured or underinsured direct buyers |
| Commercial Savings Card | As low as $25 | As low as $25 | Commercial insurance holders (exclusions apply) |
| Medicare GLP-1 Bridge | $50 flat copay | $50 flat copay | Eligible Medicare Part D beneficiaries through Dec 2027 |
Treatment Protocols Mandate Gradual Dose Escalation
Wegovy® requires a licensed prescription and cannot be purchased over the counter. Treatment protocols mandate gradual dose escalation over several weeks to mitigate gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. Medical guidelines also restrict use for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Beyond the cost of the medication itself, out-of-pocket budgeting must account for clinical oversight. Routine provider check-ins, prescription renewals, and periodic laboratory assessments add incremental expenses ranging from $150 to $300 per physician visit and $100 to $200 for lab work when utilizing standalone telehealth or in-person primary care providers.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
